eprintid: 19389
rev_number: 16
eprint_status: archive
userid: 1589
dir: disk0/00/01/93/89
datestamp: 2015-12-14 12:48:13
lastmod: 2024-03-10 03:17:24
status_changed: 2015-12-14 12:48:13
type: article
metadata_visibility: show
creators_name: Förster, Robert
creators_name: Eisele, Christian
creators_name: Bruckner, Thomas
creators_name: Bostel, Tilman
creators_name: Schlampp, Ingmar
creators_name: Wolf, Robert
creators_name: Debus, Jürgen
creators_name: Rief, Harald
title: Bone density as a marker for local response to radiotherapy of spinal bone metastases in women with breast cancer: a retrospective analysis
subjects: 610
divisions: 911400
divisions: 911800
abstract: Background: We designed this study to quantify the effects of radiotherapy (RT) on bone density as a local response in spinal bone metastases of women with breast cancer and, secondly, to establish bone density as an accurate and reproducible marker for assessment of local response to RT in spinal bone metastases.   Methods: We retrospectively assessed 135 osteolytic spinal metastases in 115 women with metastatic breast cancer treated at our department between January 2000 and January 2012. Primary endpoint was to compare bone density in the bone metastases before, 3 months after and 6 months after RT. Bone density was measured in Hounsfield units (HU) in computed tomography scans. We calculated mean values in HU and the standard deviation (SD) as a measurement of bone density before, 3 months and 6 months after RT. T-test was used for statistical analysis of difference in bone density as well as for univariate analysis of prognostic factors for difference in bone density 3 and 6 months after RT.   Results: Mean bone density was 194.8 HU ± SD 123.0 at baseline. Bone density increased significantly by a mean of 145.8 HU ± SD 139.4 after 3 months (p = .0001) and by 250.3 HU ± SD 147.1 after 6 months (p <.0001). Women receiving bisphosphonates showed a tendency towards higher increase in bone density in the metastases after 3 months (152.6 HU ± SD 141.9 vs. 76.0 HU ± SD 86.1; p = .069) and pathological fractures before RT were associated with a significantly higher increase in bone density after 3 months (202.3 HU ± SD 161.9 vs. 130.3 HU ± SD 129.2; p = .013). Concomitant chemotherapy (ChT) or endocrine therapy (ET), hormone receptor status, performance score, applied overall RT dose and prescription of a surgical corset did not correlate with a difference in bone density after RT.   Conclusions: Bone density measurement in HU is a practicable and reproducible method for assessment of local RT response in osteolytic metastases in breast cancer. Our analysis demonstrated an excellent local response within metastases after palliative RT.  
date: 2015
publisher: BioMed Central
id_scheme: DOI
ppn_swb: 1653705426
own_urn: urn:nbn:de:bsz:16-heidok-193892
language: eng
bibsort: FORSTERROBBONEDENSIT2015
full_text_status: public
publication: Radiation Oncology
volume: 10
number: 62
place_of_pub: London
pagerange: 1-7
issn: 1748-717X
citation:   Förster, Robert ; Eisele, Christian ; Bruckner, Thomas ; Bostel, Tilman ; Schlampp, Ingmar ; Wolf, Robert ; Debus, Jürgen ; Rief, Harald  (2015) Bone density as a marker for local response to radiotherapy of spinal bone metastases in women with breast cancer: a retrospective analysis.  Radiation Oncology, 10 (62).  pp. 1-7.  ISSN 1748-717X     
document_url: https://archiv.ub.uni-heidelberg.de/volltextserver/19389/1/13014_2015_Article_368.pdf